These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 33079169)

  • 1. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
    Wojewska DN; Kortholt A
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
    Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
    J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
    Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies.
    Leemans M; Galicia C; Deyaert E; Daems E; Krause L; Paesmans J; Pardon E; Steyaert J; Kortholt A; Sobott F; Klostermeier D; Versées W
    Biochem J; 2020 Apr; 477(7):1203-1218. PubMed ID: 32167135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides.
    Helton LG; Soliman A; von Zweydorf F; Kentros M; Manschwetus JT; Hall S; Gilsbach B; Ho FY; Athanasopoulos PS; Singh RK; LeClair TJ; Versées W; Raimondi F; Herberg FW; Gloeckner CJ; Rideout H; Kortholt A; Kennedy EJ
    ACS Chem Biol; 2021 Nov; 16(11):2326-2338. PubMed ID: 34496561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain.
    Li X; Qi Z; Ni D; Lu S; Chen L; Chen X
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L'RRK de Triomphe: a solution for LRRK2 GTPase activity?
    Nixon-Abell J; Berwick DC; Harvey K
    Biochem Soc Trans; 2016 Dec; 44(6):1625-1634. PubMed ID: 27913671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
    Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
    Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.
    Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL
    Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.
    Christensen KV; Smith GP; Williamson DS
    Prog Med Chem; 2017; 56():37-80. PubMed ID: 28314412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.